Background: Despite substantial improvements in technology and the increased demand for technology-enabled behavioral health tools among consumers, little progress has been made in easing the burden of mental illness. This may be because of the inherent challenges of conducting traditional clinical trials in a rapidly evolving technology landscape.
Objective: This study sought to validate the effectiveness of Pacifica, a popular commercially available app for the self-management of mild-to-moderate stress, anxiety, and depression.
Methods: A total of 500 adults with mild-to-moderate anxiety or depression were recruited from in-app onboarding to participate in a randomized waitlist controlled trial of Pacifica. We conducted an all-virtual study, recruiting, screening, and randomizing participants through a Web-based participant portal. Study participants used the app for 1 month, with no level of use required, closely mimicking real-world app usage. Participants in the waitlist group were given access to the app after 1 month. Measurements included self-reported symptoms of stress, anxiety, depression, and self-efficacy. We performed an intent-to-treat analysis to examine the interactive effects of time and condition.
Results: We found significant interactions between time and group. Participants in the active condition demonstrated significantly greater decreases in depression, anxiety, and stress and increases in self-efficacy. Although we did not find a relationship between overall engagement with the app and symptom improvement, participants who completed relatively more thought record exercises sustained improvements in their symptoms through the 2-month follow-up to a greater degree than those who completed fewer. In addition, we found that participants who reported concomitantly taking psychiatric medications during the trial benefitted less from the app, as measured by the symptoms of anxiety and stress.
Conclusions: This study provides evidence that Pacifica, a popular commercially available self-help app, is effective in reducing self-reported symptoms of depression, anxiety, and stress, particularly among individuals who utilize thought records and are not taking psychiatric medication.
Trial Registration: ClinicalTrials.gov NCT03333707; https://clinicaltrials.gov/ct2/show/NCT03333707 (Archived by WebCite at http://www.webcitation.org/78YE07ADB).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592477 | PMC |
http://dx.doi.org/10.2196/12556 | DOI Listing |
Psychol Trauma
January 2025
Department of Psychiatry, First Affiliated Hospital of Jinan University.
Objective: Eye movement desensitization and reprocessing therapy (EMDR) is effective in treating major depressive disorder (MDD) with childhood trauma, and virtual reality (VR) can further extend its application form. However, the utilization of VR-EMDR in treating MDD with childhood trauma is still in its infancy, and whether it can improve depressive symptoms and traumatic experience remains unknown.
Method: Seventy-two MDD patients were randomly allocated to the intervention group and the wait-list control group on a 1:1 basis.
Pharmacol Res Perspect
February 2025
Faculty of Health Sciences, Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa.
The Flinders sensitive line (FSL) rat is an accepted rodent model for depression that presents with strong face, construct, and predictive validity, thereby making it suitable to investigate novel antidepressant mechanisms. Despite the translatability of this model, available literature on this model has not been reviewed for more than ten years. The PubMed, ScienceDirect and Web of Science databases were searched for relevant articles between 2013 and 2024, with keywords relating to the Flinders line rat, and all findings relevant to treatment naïve animals, included.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Background: Behavioural changes are among the first symptoms noticeable to the person themselves as they begin to experience cognitive decline. Blood-based biomarkers could potentially be a less invasive and easily detectable biomarker for early identification of Alzheimer's disease and dementia. However, the contributions and pathobiology of blood biomarkers to disease trajectory and prevalence in Asians requires further definition.
View Article and Find Full Text PDFBackground: Biomarkers such as amyloid beta (Aβ) peptides and tau protein can correlate with changes in cognition and mood symptoms associated with AD. We aimed to investigate the blood biomarker response to a Kundalini Yoga (KY) compared to Memory Enhancement Training (MET) intervention as well as determine the predictive value of blood biomarkers on outcomes in a randomized trial targeting women at risk for Alzheimer's disease.
Method: Women aged 60 years old and older with subjective memory complaints and high cardiovascular risk score were randomized to a 12-week RCT of Kundalini yoga or Memory enhancement training (MET).
Alzheimers Dement
December 2024
German Center for Neurodegenerative Diseases (DZNE), Dresden, Germany.
Background: Increased stress, a proposed risk factor for Alzheimer's disease (AD), is associated with increased brain and cognitive vulnerabilities in older populations, which may be different in women and men.
Objective: To examine cross-sectional associations between circulating stress hormones (epinephrine, norepinephrine, cortisol, dehydroepiandrosterone sulfate (DHEAS), and DHEAS/cortisol ratio) and multimodal measures of brain health and cognition sensitive to AD.
Method: 132 cognitively unimpaired older participants without clinical depression (age = 74.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!